Home > Browse Research > Life Sciences > Diagnostics > Medical Imaging > Radiopharmaceuticals

Radiopharmaceuticals: market research reports

Radiopharmaceuticals are radioactive pharmaceuticals used in medical imaging as tracers for the identification and diagnosis of many illnesses. Nuclear medicine modalities – SPECT and PET – use radiopharmaceuticals to generate diagnostic images. These nuclear pharmaceuticals combine physiologically active carriers with a radioisotope. It is possible to manufacture chemical or biological carriers which migrate to a particular part of the human body.

For example, iodine concentrates in the thyroid gland. The radioisotope attached to these compounds emits radiation so that the relevant organ and its functioning can be imaged.

A radiopharmaceutical, which involves the use of radioactive agents in vivo to diagnose or treat specific diseases and conditions, generally consists of two components which determine its characteristics and clinical potential. The most common diagnostic molecular imaging agents use radioactive isotopes as the signal source. A radioactive isotope -- a radioisotope or radionuclide -- is a natural or artificially created isotope with an unstable nucleus that decays -- emitting alpha or beta particles, positrons, or gamma rays. As it decays, it loses mass and energy, until a stable isotope develops. For most elements, both stable and radioactive isotopes are known.

Examples of radioisotopes commonly combined with pharmaceutically-active molecules to form radiopharmaceuticals include technetium-99m, gallium-67, Iodine-123, Iodine-13, Thallium-201, Fluorine-18, and Indium-111.

A number of SPECT radiopharmaceuticals incorporate antibody and peptide formulations that can be targeted to specific tissue receptors, allowing one to discriminate healthy from diseased tissue with a high confidence level. However, the more specific the targeting agent is, the more difficult it is to interpret its position anatomically, since there are fewer landmarks.

Radiopharmaceuticals market research reports and industry analysis

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017 4/18/2013 \| published by: MarketsandMarkets ... Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s ... \| read more...	$4,650.00
Advances in Molecular Imaging: A market coming of age 4/9/2013 \| published by: Espicom Healthcare Intelligence ... to peg back the sector’s growth. But since 2010 things have improved; pressure in the US market has eased and growth has come from increasing demand in emerging markets such as India and China. The ... \| read more...	$1,740.00
European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017 4/8/2013 \| published by: MarketsandMarkets ... (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer’s ... \| read more...	$4,650.00
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017 4/3/2013 \| published by: MarketsandMarkets ... (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in ... \| read more...	$4,650.00
Medical Imaging Markets: Contrast Agents (X-Ray, CT, Ultrasound, MRI, PET, SPECT) 7/9/2012 \| published by: Kalorama Information ... body’s internal structures, organs and tissue that would nototherwise be clearly seen. Although bones are readily apparent on radiographic images, other organs and tissues are not. These imaging agents may be usedduring a medical imaging ... \| read more...	$3,995.00
Imaging Agents 2/1/2012 \| published by: Global Industry Analysts ... US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. ... \| read more...	$4,500.00
Radiopharmaceuticals 10/1/2011 \| published by: Global Industry Analysts ... 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare ... \| read more...	$4,500.00
Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 - 2015) 8/1/2011 \| published by: MarketsandMarkets ... radiopharmaceuticals as tracer dates back to 1930’s. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and ... \| read more...	$4,650.00
Imaging Agents 2/1/2011 \| published by: Global Industry Analysts ... US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. ... \| read more...	$4,500.00
The 2011-2016 World Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use 1/20/2011 \| published by: Icon Group International, Inc. ... (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country ... \| read more...	$795.00
Advances in SPECT Imaging (Technical Insights) 12/31/2010 \| published by: Frost & Sullivan ... restraints, various technology innovations and analysis of stakeholders, assessment of industry initiatives with Analytical Hierarchy Process(AHP) based competitive bench marking of imaging modalities for cardiac imaging. Finally a list of patents pertaining to SPECT instrumentation ... \| read more...	$6,500.00
US Markets for Contrast Agents and Radiopharmaceuticals 2011 11/24/2010 \| published by: Millennium Research Group ... care costs. This began with cost-containment measures spurred by rising diagnostic imaging procedures prior to reimbursement cuts under the 2005 Deficit Reduction Act. Many insurers are mandating the preauthorization of imaging scans before coverage can ... \| read more...	$4,337.00
Emerging Technology Developments in Hybrid Imaging (Technical Insights) 9/30/2010 \| published by: Frost & Sullivan ... drivers, restraints and challenges, diffusion of innovations assessment which include application-wise and region-wise adoption potential of the various hybrid imaging modalities discussed, analysis of end user demands, opportunities and strategic recommendations. Finally a list of ... \| read more...	$6,500.00
Medical Imaging Markets: Contrast Agents 11/1/2009 \| published by: Kalorama Information ... in order. This bodes well for contrast media markets. Since our last round-up of the contrast media market, the economic environment in the world has changed. Although the recession may have caused hospitals, physician offices ... \| read more...	$3,500.00
The 2009-2014 World Outlook for Diagnostic Radiopharmaceuticals 1/8/2009 \| published by: Icon Group International, Inc. ... question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... \| read more...	$795.00
The 2009 Report on Diagnostic Radiopharmaceuticals: World Market Segmentation by City 1/5/2009 \| published by: Icon Group International, Inc. ... as opposed to regions, continents, or countries. This report covers the top 2000 cities in over 200 countries. It does so by reporting the estimated market size (in terms of latent demand) for each major ... \| read more...	$795.00
The 2009-2014 Outlook for Diagnostic Radiopharmaceuticals in Japan 12/2/2008 \| published by: Icon Group International, Inc. ... 1,000 cities in Japan. For each city in question, the percent share the city is of it’s prefecture and of Japan is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis ... \| read more...	$495.00
The 2009-2014 Outlook for Diagnostic Radiopharmaceuticals in Greater China 12/2/2008 \| published by: Icon Group International, Inc. ... special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as “regions”). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in ... \| read more...	$495.00
The 2009-2014 Outlook for Diagnostic Radiopharmaceuticals in India 12/2/2008 \| published by: Icon Group International, Inc. ... across over 5,000 cities in India. For each city in question, the percent share the city is of it’s state or union territory and of India as a whole is reported. These comparative benchmarks allow ... \| read more...	$495.00
The 2009-2014 Outlook for Diagnostic Radiopharmaceuticals in the United States 12/2/2008 \| published by: Icon Group International, Inc. ... across some 12,900 cities in the United States. For each city in question, the percent share the city is of it’s state and of the United States is reported. These comparative benchmarks allow the reader ... \| read more...	$495.00
U.S. Radiopharmaceutical Agents Markets 6/3/2008 \| published by: Frost & Sullivan ... eleven year period, from 2004 to 2014, with the base year being 2007. The research service provides a comprehensive analysis and forecasts for revenue by segment, demand analysis including data on procedure volumes, procedure types, ... \| read more...	$8,500.00
Imaging Agents (Contrast Media, Radiopharmaceuticals) 5/1/2008 \| published by: Global Industry Analysts ... the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche ... \| read more...	$3,950.00
Medical Imaging Markets, Volume IV: Contrast Agents 2/1/2007 \| published by: Kalorama Information ... growing marketplace in these agents. The introduction and now brisk ongoing development of contrast media for traditional radiography, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron-emission tomography (PET), and single-photon emission computed tomography (SPECT), ... \| read more...	$1,995.00
The European Contrast Media and Radiopharmaceuticals Markets 10/15/2004 \| published by: Frost & Sullivan ... contrast media market, the introduction of new technologies that require less contrast agents - such as helical and spiral computed tomography (CT) - is limiting the growth of the X-ray/CT segment. On the other hand, ... \| read more...	$6,800.00
U.S. Radiopharmaceuticals Markets 5/1/2002 \| published by: Frost & Sullivan ... prior to structural change. Commercial development of alpha-emitters, for example, will provide radiologists with better tools to target tumor cells and offer new opportunities for pharmaceutical firms. This research analyzes the U.S. markets for radiopharmaceuticals, ... \| read more...	$3,950.00